Health
DC Diagnosis Newsletter: Lipton Tea, Grindr Healthcare Lobbying
You are reading the web edition of DC Diagnosis, STAT’s biweekly newsletter about politics and policy in the field of health and medicine. Sign up here and receive it in your inbox on Tuesdays and Thursdays.
Hard bargain or barely a bargain?
The deadline for Medicare to release negotiated prices for the first round of drugs is fast approaching. If you’re wondering how to determine whether the Biden administration got a raw deal, my colleague John Wilkerson has some tips.
Assessing negotiated prices isn’t easy, but there are at least four ways to find out. Do they save taxpayers money? Are they saving seniors’ money? Are they priced appropriately for the value they provide? Do we still pay more than other countries?
This article is exclusive to STAT+ subscribers
Unlock this article – plus in-depth analysis, newsletters, premium events and access to networking platforms.
Do you already have an account? Log in
Do you already have an account? Log in
View all subscriptions
Get unlimited access to award-winning journalism and exclusive events.
Subscribe
